Uppsala 7th January 2019


Nanexa invests to meet increased demand

Nanexa has placed an order for another reactor for Atomic Layer Deposition (ALD) from the Finnish company Picosun. Picosun manufactures commercial ALD reactors and Nanexa’s two previous ALD reactors are also purchased from them.

ALD is Nanexa’s core technology and the technology used by the Company to produce its drug delivery platform PharmaShell®, which provides opportunities to control drug release after parenteral administration.

The new ALD reactor, which will be installed at the beginning of the second quarter of 2019, is a reactor with larger capacity and Nanexa can thus increase the production of test material for the Company’s collaboration project with various partners.

The purchase of the reactor is financed under the expansion loan from ALMI that Nanexa has already granted.


Nanexa’s CEO David Westberg comments:

We see that with the new collaborations that have just started and potentially upcoming collaborative projects, the ALD capacity in our laboratory in Uppsala will need to be expanded in order not to become a time-limiting factor in the company’s development. The new ALD reactor will both increase capacity so that we can work in parallel in several projects and it will also be important in the work to scale-up the manufacturing process.

The last year has been Nanexa’s most successful so far, with the start of several collaborations, that has previously been communicated. With the new ALD reactor, we have the opportunity to further increase the pace of our development and quickly deliver materials to our partners. 


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.